Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.69 |
| ▸ | CTSD | P07339 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | ALPL | P05186 | 1/20 | 0.58 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.58 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15997924 | 0.86 | ALDH1A1 (0.80) | ALDH1A1CTSDKDM4EMAPTCYP1A2 | |
| SCHEMBL27602570 | 0.84 | TSHR (0.68) | ALDH1A1SLC6A2SLC6A4SLC6A3MAPT | |
| SCHEMBL12260755 | 0.84 | CRHBP (0.62) | ALDH1A1SLC6A2SLC6A4SLC6A3CTSD | |
| SCHEMBL6971514 | 0.83 | ALDH1A1 (0.76) | ALDH1A1CTSDKDM4EMAPTCYP1A2 | |
| SCHEMBL31621278 | 0.83 | ALDH1A1 (0.76) | ALDH1A1CTSDKDM4EMAPTCYP1A2 | |
| SCHEMBL296470 | 0.83 | ALDH1A1 (0.76) | ALDH1A1CTSDKDM4EMAPTCYP1A2 | |
| SCHEMBL2508349 | 0.83 | SLC6A2 (0.58) | ALDH1A1SLC6A2SLC6A4SLC6A3CTSD | |
| SCHEMBL13070932 | 0.83 | SLC6A2 (0.58) | ALDH1A1SLC6A2SLC6A4SLC6A3CTSD | |
| SCHEMBL430054 | 0.83 | SLC6A2 (0.58) | ALDH1A1SLC6A2SLC6A4SLC6A3CTSD | |
| SCHEMBL11909404 | 0.83 | SLC6A2 (0.58) | ALDH1A1SLC6A2SLC6A4SLC6A3CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118043459-A | Chemically modified oligonucleotides | 菲奥医药公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-111072571-B | Dithiocarbamates as FAK inhibitors | 北京西博医药研究有限公司 | 2021-05-14 | — | — | CN | disclosed |
| CN-111072571-A | Dithiocarbamates as FAK inhibitors | 北京西博医药研究有限公司 | 2020-04-28 | — | — | CN | disclosed |
| CN-109996546-A | P2X3And/or P2X2/3Compounds and methods | 阿沙纳生物科学公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-108707139-A | Amino-metadiazine compound and its preparation method and application | 北京浦润奥生物科技有限责任公司 | 2018-10-26 | — | — | CN | disclosed |
| CN-104703976-B | Double (fluoroalkyls) 1,4 benzodiazepine * assimilation compound is used as NOTCH inhibitor | 百时美施贵宝公司 | 2017-03-08 | — | — | CN | disclosed |
| US-20160039789-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | disclosed |
| CN-104703976-A | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors | BRISTOL MYERS SQUIBB CO | 2015-06-10 | — | — | CN | disclosed |
| US-8765773-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| CN-102666540-A | Fused azine derivatives for the treatment of acetylcholine receptor related diseases | MSD OSS BV | 2012-09-12 | — | — | CN | disclosed |
| EP-0763524-B1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO CO (JP) | 2000-08-23 | — | — | EP | disclosed |
| US-5965576-A | Cyclic amide derivatives for treating asthma | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| US-5705505-A | Cyclic amide derivatives for treating asthma | ZENECA LIMITED (GB) | 1998-01-06 | — | — | US | disclosed |
| EP-0763524-A1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |
| CN-1142822-A | Cyclic amide derivatives as neurokinin A antagonists | ZENECA LTD (GB) | 1997-02-12 | — | — | CN | disclosed |
| US-5589489-A | Cyclic amide derivatives for treating asthma | ZENECA LIMITED (GB) | 1996-12-31 | — | — | US | disclosed |
| EP-0734383-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1996-10-02 | — | — | EP | disclosed |
| EP-0371564-B1 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-07-12 | — | — | EP | disclosed |
| WO-1995016682-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1995-06-22 | — | — | WO | disclosed |
| EP-0371564-A2 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039789-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | ALDH1A1 298/4885SLC6A2 4058/4885SLC6A4 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.